Stryker and Zimmer Biomet
Roche began in the early 2000s in US commercial and leadership roles at Stryker. He later became global president of robotics and technology at Zimmer Biomet, where he led the global launch of the ROSA robotic knee system and developed business models for ambulatory surgery centers.1
He then served as CEO of Avateramedical, a German soft-tissue surgical robotics company.1
Distalmotion
Roche joined Distalmotion as CEO in December 2023. Under Roche, Distalmotion has focused on US ambulatory surgery centers and raised $70 million in financing from Perceptive Advisors.4,2
He told MedTech Dive that DEXTER passed 3,000 cumulative procedures across Europe and the US in the fourth quarter of 2025, and that the following quarter was the company's best yet.3
The industry needs solutions that remove barriers and improve efficiency, not just more robotic systems.Greg Roche, Distalmotion announcement
Links
Sources
- DeviceTalks Boston, Greg Roche speaker profile, accessed November 2, 2026
- MD+DI, Why ASCs need robots built for them, not retrofitted from hospitals, accessed November 2, 2026
- MedTech Dive, Surgeries are moving to ASCs. Distalmotion wants its robot to drive the shift., accessed November 2, 2026
- Distalmotion, Distalmotion accelerates US commercial momentum in ASCs, May 21, 2026, accessed November 2, 2026
